Health Canada To Consider Follow-On Biologics Proposal In May
This article was originally published in The Pink Sheet Daily
Executive Summary
"Subsequent Entry Biologics" would not automatically receive indications held by the reference product, draft guidance says.
You may also be interested in...
Sandoz Will Launch Biosimilar Epoetin Alfa In Europe At Up To 30 Percent Discount To Branded Products
EU approval further demonstrates need for U.S. follow-on pathway, Sandoz VP-Global Head of Biopharma Development Ajaz Hussain tells “The Pink Sheet” DAILY.
Sandoz Omnitrope Gains First “Similar Biological” Positive Opinion In the EU
Recombinant-DNA growth hormone would be approved through new pathway by demonstrating comparable safety and efficacy to Genotropin.
Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.